Clinical Trials · NCT00707031
GLP-1 Receptor Agonist Lixisenatide Versus Exenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Metformin
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- Sanofi
- Enrollment
- 639
- Start date
- Jun 2008
- Locations
- 18 sites, 18 countries
- Primary endpoint
- Absolute Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24